Skip to content

The Beauty Health Company SKIN Free cash flow margin

Free cash flow margin at other companies

AbbVie logo
AbbVieABBV
31.8%+5.0pp
Solesence, Inc. Common Stock logo
Solesence, Inc. Common StockSLSN
-20.1%
Lifevantage Corporation logo
Lifevantage CorporationLFVN
3.8%+1.1pp
Estee Lauder Companies Inc. logo
Estee Lauder Companies Inc.EL
8.7%+2.3pp
SANUWAVE Health, Inc. logo
SANUWAVE Health, Inc.SNWV
9%
NuSkin Enterprises logo
NuSkin EnterprisesNUS
2.9%-1.0pp

Other financials

Income statement

See full
Revenue$64.9M-6.7%
Gross profit$44.4M-8.5%
Operating income-$1.8M+85.0%
Net income-$6.6M+34.3%
EPS (diluted)-$0.05+37.5%

Balance sheet

See full
Cash & equivalents$204.4M-45.2%
Total debt$125.9M+756%
Total equity$55.2M+19.9%
Total assets$473.2M-29.8%

Cash flow

See full
Operating cash flow-$5.6M-285%
CapEx$224.0K+398%
Free cash flow-$5.8M-296%

Valuation

See full
Market cap$89.75M-63.3%
Enterprise value$11.24M-97.3%
P/S0.3×-0.5×

Profitability

See full
Gross margin64.9%+8.3pp
Operating margin-3.6%-1.6pp
Net margin-2%-0.9pp

Returns & leverage

See full
Return on equity-12%-5.4pp
Debt / equity2.3×+2.0×
Current ratio1.8×-5.7×

Where this comes from

Calculated from The Beauty Health Company’s reported figures.

Based on trailing twelve months.

The official record: The Beauty Health Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about The Beauty Health Company's free cash flow margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is The Beauty Health Company's free cash flow margin?
The Beauty Health Company (SKIN) reported free cash flow margin of 9.6% in Q1 2026.
What is the long-term trend for The Beauty Health Company's free cash flow margin?
Over 2 years (2021 to 2025), The Beauty Health Company's free cash flow margin has grown at a -10.0% compound annual growth rate (CAGR), from -15.3% to 12.4%.
What does free cash flow margin mean?
Free cash flow (operating cash flow minus capital expenditures) as a percentage of revenue, trailing twelve months. Measures how efficiently revenue converts into discretionary cash.